SCHEMBL1787498

SCHEMBL1787498

COc1ccc2c(c1)c(C=O)cn2C(C)C

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
HTR6 P50406 1/20 0.53
PDE4B Q07343 1/20 0.47
PDE4D Q08499 1/20 0.47
BCHE P06276 7/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
PTGER4 P35408 1/20 0.45
ERN1 O75460 1/20 0.44
TRIM24 O15164 1/20 0.44
TYR P14679 1/20 0.44
TRIM33 Q9UPN9 1/20 0.44
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
ACHE P22303 5/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL670809 0.88 ALDH1A1 (0.67) ALDH1A1HTR6PDE4BPDE4DBCHE
SCHEMBL1093582 0.80 ALDH1A1 (0.77) ALDH1A1HTR6BCHECYP1A2CYP2C19
SCHEMBL12182481 0.79 ALDH1A1 (0.65) ALDH1A1KDM4E
SCHEMBL671605 0.79 PDE4B (0.46) ALDH1A1PDE4BERN1KDM4E
SCHEMBL10067352 0.78 HTR6 (0.58) ALDH1A1HTR6PDE4BPDE4DBCHE
SCHEMBL12614442 0.78 HTR6 (0.58) ALDH1A1HTR6PDE4BPDE4DKDM4E
SCHEMBL2316115 0.77 HTR6 (0.57) ALDH1A1HTR6PDE4BPDE4DBCHE
SCHEMBL1785990 0.77 BCHE (0.57) ALDH1A1HTR6BCHEPTGER4KDM4E
SCHEMBL1429401 0.76 BCHE (0.59) ALDH1A1BCHEACHE
SCHEMBL15902083 0.75 AKR1C3 (0.57) ALDH1A1BCHECYP1A2CYP2C19PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110124674-A1 5/5-OR 5/6-MEMBERED CONDENSED RING CYCLOALKYLAMINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-05-26 US disclosed
US-20110124674-A1 5/5-OR 5/6-MEMBERED CONDENSED RING CYCLOALKYLAMINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-05-26 US disclosed
EP-2319841-A1 (5-MEMBERED)-(5-MEMBERED) OR (5-MEMBERED)-(6-MEMBERED) FUSED RING CYCLOALKYLAMINE DERIVATIVE MSD K.K. (JP) 2011-05-11 EP disclosed
EP-2319841-A1 (5-MEMBERED)-(5-MEMBERED) OR (5-MEMBERED)-(6-MEMBERED) FUSED RING CYCLOALKYLAMINE DERIVATIVE MSD K.K. (JP) 2011-05-11 EP disclosed
WO-2010013595-A1 (5-MEMBERED)-(5-MEMBERED) OR (5-MEMBERED)-(6-MEMBERED) FUSED RING CYCLOALKYLAMINE DERIVATIVE 萬有製薬株式会社 (JP) 2010-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124674-A1 5/5-OR 5/6-MEMBERED CONDENSED RING CYCLOALKYLAMINE DERIVATIVE MCHR1, MC5R, MCHR2 ALDH1A1 1615/4885HTR6 42/4885PDE4B 2080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.